bluuebunny/crossref_metadata_2025_split huggingface dataset:
CD10+ cell population in the bone marrow of patients with advanced neuroblastoma
Authors: Mandel Mathilda , Rechavi Gideon , Neumann Yoram , Biniaminov Miriam , Rosenthal Esther , Toren Amos , Brok‐Simoni Frida , Ben‐Bassat Isaac , Ramot Bracha 
Published: February 2007

AbstractImmunocytologic analyses of bone marrow can provide clinically useful prognostic information in neuroblastoma. While analyzing the bone marrow with a panel of monoclonal antibodies, which detect neuroblasts and other defining B‐, T‐, and myloid lineage, we identified two infants with stage IV‐S neuroblastoma whose bone marrow contained a large population of common acute lymphoblastic leukemia (ALL)‐like cells. This population expressed HLA‐DR, CD19(B1), CD10(CALLA), and occasionally CD20(B1). Since 1988, 17 additional patients with advanced neuroblastoma (IV‐S, III, and IV) were studied by us. In 10 of the 19 patients, the bone marrow revealed an expanded CD10 population (20‐70%). It appears that this group of patients has a better prognosis. Out of 9 patients who did not have an expanded CD10 population, 8 died within 9 months from diagnosis, whereas out of 10 patients with an expanded CD10 population only one died and the others are alive, 6‐30 months from diagnosis (P < 0.001). An expanded CD10 population in the bone marrow of disseminated neuroblastoma patients may therefore serve as a prognostic factor. Apart from the prognostic value of this particular population in the single patient, its presence may shed light on the interrelationship between the immune system and the neuroendocrine compartment. © 1994 Wiley‐Liss, Inc.
Pilot study of sequential combination chemotherapy in advanced and recurrent retinoblastoma
Authors: Advani S. H. , Rao S. R. , Lyer R. S. , Pai S. K. , Kurkure P. A. , Nair C. N. 
Published: February 2007

AbstractEight patients with advanced/recurrent retinoblastomas were treated with sequential combination chemotherapy incorporating cyclophosphamide, cisplatin, adriamycin, and etoposide. All patients achieved complete clinical response (CR) at the end of the first 75 day cycle. Three patients developed recurrence of which 2 patients had recurrence in the central nervous system and 1 patient had local recurrence. Median time to treatment failure was 30 weeks. Two patients succumbed to chemotherapy related neutropenic sepsis. One patient is alive and disease free for 72 weeks from start of treatment. This combination chemotherapy shows promise in patients with advanced/recurrent retinoblastoma and merits further Study. © 1994 Wiley‐Liss, Inc.
Management of pineal non‐germinoma germ cell tumor with residual teratoma and normal alpha‐fetoprotein
Authors: Nashold James R. B. , Oakes W. Jerry , Friedman Henry S. , Halperin Edward C. , Soo Mary , Hockenberger Beverly , Fuller Gregory N. , Tien Robert 
Published: February 2007

AbstractA 16‐year‐old white male presented with multiple abnormal extraocular movements secondary to an enhancing pineal tumor. Subtotal resection of the lesion revealed a mixed malignant germ cell tumor. The pre‐operative serum alpha‐fetoprotein (AFP) was markedly elevated at 155 IU/L. The patient subsequently received radiotherapy and adjuvant chemotherapy consisting of cisplatin rotating monthly with vincristine and cyclo‐phosphamide, with dramatic tumor regression and return of AFP to normal. Eighteen months later the persistence of a substantial tumor mass despite a normal AFP raised concern for residual active tumor. Histological examination of the resected lesion revealed benign teratoma and fibrous tissue. Repeat surgical intervention may contribute to the management of mixed malignant germ cell tumors, which demonstrate a persistent mass following an initial response to treatment. © 1994 Wiley‐Liss, Inc.
Childhood anaplastic large cell lymphoma Ki‐1/CD30: Clinicopathologic features of 19 cases
Authors: Rubie Hervé , Gladieff Laurence , Robert Alain , Gaubert Isabelle , Huguet Françoise , Rochaix Philippe , Pein François , Michel Gérard , Hoerni Bernard , Sommelet Danièle , Delsol Georges 
Published: February 2007

AbstractThe authors report their cumulative experience of 19 children with what was previously called malignant histiocytosis (MH) but is now considered a true lymphoma and termed anaplastic large cell lymphoma (ALCL). The median age at diagnosis was 10 years and 6 months (range 2 y, 11 m, to 15 y). There were 13 males and 6 females. Most cases presented with fever, wasting and enlarged, often tender, lymph nodes. Other features were: fleeting cutaneous rashes in 7 cases; spontaneous regression of lymph nodes and skin lesions were seen in 5 patients. Bone marrow involvement was present in 3 cases, pulmonary infiltrate in 5, kidneys in 2, and central nervous system in none. The morphology of lymph node involvement was consistent with so‐called MH, a description originally applied to sinusoïdal infiltration by large „histiocytic”︁ cells. The coexpression of lymphoid activation antigens Ki‐1/CD 30 (18/19), epithelial membrane antigen EMA (18/19) and interleukin‐2 receptor/CD 25 (10/10) was the unifying immunopathologic feature of the neoplasm. Lineage antigens were not identifiable in 8/19 instances (null phenotype), while 10/19 expressed a T‐cell phenotype. None of the tumors expressed histiocytic markers. After variable, but intensive, combination chemotherapy, 15 children out of 18 evaluable achieved complete remission (CR). Among all patients, thirteen are still alive in CR (ten in first CR) with a median follow‐up of 5 years. This evaluation in the pediatric age group reinforces that so‐called MH is a lymphoid neoplasm, a conceptual change that could lead to improved understanding and therapy.© 1994 Wiley‐Liss, Inc.
Randomized study for the treatment of adult advanced Hodgkin's disease: Epirubicin, vinblastine, bleomycin, and dacarbazine (EVBD) versus mitoxantrone, vinblastine, bleomycin, and dacarbazine (MVBD)
Authors: Avilés Agustín , Guzmán Renaldo , Talavera Alejandra , García Edna L. , Díaz‐Maqueo José C. 
Published: February 2007

AbstractSeventy patients with previously untreated advanced Hodgkin's disease and without bulky disease were entered in a prospective randomized clinical trial comparing epirubicin in combination with vinblastine, bleomycin, and dacarbazine (EVBD) with a regimen containing mitoxantrone, vinblastine, bleomycin, and dacarbazine (MVBD). Both groups were comparable for the variables of age, sex, stage, and presence of B symptoms and histology. Thirty‐one (88%) of EVBD‐treated patients achieved a pathologically documented complete remission (CR) compared to the 24 cases (68%) of the MVBD‐treated group. After a median follow‐up of 36 months, duration of CR is better in the EVBD‐treated patients with an actuarial 5‐year duration of CR of 80%, statistically different to the MVBD group: 53% (P < 0.01). Both regimens ahowed the same gastrointestinal toxicity, but the patients treated with the MVBD regimen shown most and severe hematological and cardiac toxicities. Also, biochemical alterations in hepatic test were observed in these patients. The alternative use of epirubicin in combination chemotherapy appears to be as effective in advanced Hodgkin's disease without bulky disease, with reduced clinical toxicity. Mitoxantrone containing regimen was not found to have an equivalent efficacy and clinical toxicity was most frequent and severe. We feld that mitoxantrone could be consider a second‐line drug in the treatment of advanced Hodgkin's disease. © 1994 Wiley‐Liss, Inc.
False positive results in a neuroblastoma screening programme
Authors: Bell Susan , Parker Louise , Craft Alan W. , Dale Gordon , McGill Andrew C. , Seviour John , Cole Michael , Smith Julian 
Published: February 2007

AbstractTwenty thousand, eight hundred and twenty‐nine babies were screened for neuroblastoma at 6 months of age by measuring homovanillic (HVA) and vanillylmandelic (VMA) acid in urine and ratioing these to creatinine. Using a „cut off”︁ of the mean + 3 SD, 10 were found to be positive. Two were found on evaluation to have neuroblastoma and in the remaining 8 the raised levels of HVA and/or VMA returned to normal. Only one of the 8 false positive babies was absolutely normal, most having a chronic disorder or illness. Utilising new centiles which relate HVA and VMA to creatinine, only 3 of the 8 would have remained positive, a false positive rate of 0.01%. The false negative rate would have remained unchanged.
Malignant histiocytosis and large cell anaplastic (Ki‐1) lymphoma in childhood: Guidelines for differential diagnosis—report of the histiocyte society
Authors: Bucsky Peter , Favara Blaise , Feller Alfred C. , Nezelof Christian , Radzun Heinz‐Jochen , Schlegelberger Brigitte , Janka‐Schaub Gritta 
Published: February 2007

AbstractA workshop of the Histiocyte Society was recently held, in order to discuss the problems and confusion of malignant histiocytosis (MH) and large cell anaplastic (Ki‐1) lymphoma (LCAL). The aims of this workshop were to clarify the terminology for malignant histiocytic disorders and LCAL and to produce reliable criteria for diagnosis of both MH and LCAL. This article summarises the conclusions reached. © 1994 Wiley‐Liss, inc.
Bone scintigraphy in nonsurgically treated Ewing's sarcoma at diagnosis and follow‐up: Prognostic information of the primary tumor site
Authors: Hugenholtz Elise A. L. , Piers Do A. , Kamps Willem A. , Cohen Ian J. , Lerman Chedva , Lubin Ernesto , Zaizov Rina 
Published: February 2007

AbstractIn order to detect skeletal metastases in patients with Ewing's sarcoma, bone scanning is commonly used. However, little information is available about the scintigraphic aspects of the primary Ewing's sarcoma during non‐surgical treatment and follow‐up. We studied retrospectively the significance of bone scintigraphic findings at the primary tumor site of 58 patients with a Ewing's sarcoma. These patients had chemotherapy and radiotherapy. At presentation 53/58 patients showed an increased tracer uptake at the primary tumor site while 5 patients with a pelvic or sacral bone localization had a normal scan. Bone scans made during treatment and more than 2 years thereafter in the 32 eligible patients demonstrated three patterns. In 16 patients the hot spot disappeared and no local tumor recurrence was encountered. In the other 16 patients the high uptake at the primary tumor site either persisted or diminished first to a normal uptake after a median period of 18 months (range 12‐36 months) and returned again to a high uptake within 6‐12 months. In these patients local Ewing's sarcoma was still present in 13, while in the other 3 cases a benign disorder (fracture, ectopic bone formation) was the underlying cause. These findings suggest that in non‐surgically treated Ewing's sarcoma persisting increased tracer uptake or its recurrence is highly suspicious for the presence of Ewing's sarcoma, while bone scans becoming negative and remaining so for more than 12 months suggest the absence of local tumor. © 1994 Wiley‐Liss, Inc.
Cytosine arabinoside and mitoxantrone treatment of relapsed or refractory childhood leukemia: Initial response and relationship to multidrug resistance gene 1
Authors: Wells Robert J. , Odom Lorrie F. , Gold Stuart H. , Feusner James , Krill Carl E. , Waldron Peter , Moulton Thomas A. , Knoppell Eva , White Michael L , Cairo Mitchell S. 
Published: February 2007

AbstractThe objective of this study was to determine the response rate and toxicity of high‐dose cytosine arabinoside (AC) and mitoxantrone (M) in relapsed or refractory childhood acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL) and to correlate response with the expression of the multidrug resistance gene 1 (mdr1). Twenty‐nine patients were treated with AC 1.0 g/m2 infused over 2 h every 12 h for eight doses (days 1‐4) and M 12 mg/m2 infused over 1 h (days 3‐6). Mdr1 expression was determined by a polymerase chain reaction (per) assay. Ten of 15 patients (67%) with AML obtained a complete remission (CR) of 3 to 30+ months duration. Eight of 14 (57%) ALL patients obtained a CR of 1 to 23+ months duration. The major toxicities were hematopoietic and infectious. Seventy‐nine per cent of patients developed a documented infection during induction. Mdr1 did not correlate with a lower induction rate. This AC/M regimen is active in childhood AML and ALL. © 1994 Wiley‐Liss, Inc.
Pituitary adenoma and unexpected sudden infant death: A case report
Authors: Matsuura Hiroyuki , Kitazawa Yoshiaki , Tanaka Munehumi , Morooka Keiichi 
Published: February 2007

AbstractPituitary adenomas can cause sudden death in adults, but they are quite rare during infancy. Herein we present an unusual case of sudden infant death associated with a pituitary adenoma. The clinical presentations were „quietness”︁ complained of by the parents and probable gigantism with accelerated growth rate during the first 2 months of life. The female infants had been in good health until one day when, at the age of 3 months, she was found immobile in bed. Microscopic examination showed that the cells of the entire pituitary gland were replaced by bizarre undifferentiated tumor cells. There were no invasive lesions in the surrounding brain tissue. It was also found that the cortex of the adrenal glands was atrophic. No metastatic lesions were observed in any organ. While the mechanism leading our infant to death is both controversial and unknown, we speculated that insufficient secretion of steroid hormones might have caused cardiovascular collapse. © 1994 Wiley‐Liss, Inc.
Malignant lymphoma with primary cardiac manifestations: A case report
Authors: Stein Moshe , Zyssman Isaac , Kantor Angelo , Spencer Dave , Lewis Dorothy , Bezwoda Werner 
Published: February 2007

AbstractThis case report describes a 29‐year‐old black patient presenting with right heart failure secondary to massive lymphomatous cardiac involvement. Additional sites of involvement included mesenteric lymph nodes and the small bowel. Malignant lymphoma with primary cardiac manifestations is very rare and follows an aggressive course. The importance of early diagnosis and commencement of immediate therapy is emphasized. © 1994 Wiley‐Liss, Inc.
Second primary neoplasms in a population‐based series of patients diagnosed with renal tumours in childhood
Authors: Hartley Ann L. , Birch Jillian M. , Blair Valerie , Jones Patricia Morris , Gattamaneni H. Rao , Kelsey Anna M. 
Published: February 2007

AbstractEight second malignant tumours developed in a population‐based series of 218 patients diagnosed with renal tumours in childhood: renal cell carcinoma of the contralateral kidney, hepatocellular carcinoma, Hodgkin's disease, and 4 basal cell and 1 squamous cell carcinomas of skin. Excess risk of developing a second malignancy (excluding skin carcinomas but including a registrable spinal neurofibroma) was 14.7 (95% Cl 4.0‐37.7, P = 0.0003) for Wilms' tumour patients. Cumulative incidence of second malignant neoplasms (excluding skin carcinoma) was zero at 10 years, 5.0% at 20 years, and 10.2% at 30 years. The most common second neoplasms seen were benign osseous/chondromatous tumours and 4 of the 7 Wilms' tumour patients with malignant tumours had previous or synchronous tumours of this kind. Development of bony exostoses may be a marker for those patients at particularly high risk of subsequent malignancy. © 1994 wiley‐Liss, Inc.
Immunosuppression: Preliminary results of alternative maintenance therapy for familial hemophagocytic lymphohistiocytosis (FHL)
Authors: Loechelt Brett J. , Egeler Maarten , Filipovich Alexandra H. , Jyonouchi Harumi , Shapiro Ralph S. 
Published: February 2007

AbstractHemophagocytic lymphohistiocytosis (HLH) describes a group of disorders with similar clinical features that are associated with a very high mortality rate. Patients with HLH, and particularly the infantile form referred to as familial hemophagocytic lymphohistiocytosis (FHL), are often treated with multiple courses of epipodophyllotoxins, such as etoposide, for prolonged periods of time. Because of the concern regarding the risk of epipodophyllotoxin‐induced acute myelogenous leukemia (AML) we have explored the use of immunosuppression as maintenance therapy for patients with FHL while they await the only known definitive treatment, i.e., bone marrow transplantation (BMT). We report 2 infants with FHL who had significant central nervous system involvement at diagnosis. Both were initially treated with etoposide, methotrexate, and glucocorticosteroids. Once clinical improvement was achieved these patients were successfully maintained in clinical remission of FHL on daily cyclosporine A (CSA) and glucocorticosteroids along with intermittent intrathecal methotrexate for 5 months until appropriate unrelated donors could be identified for BMT.
Mitoxantrone, 5‐fu, and leucovorin in breast cancer
Authors: Swain Sandra M. , Honig Susan Flamm 
Published: February 2007

AbstractEighteen patients (17 evaluable for response) with metastatic breast cancer were treated with mitoxantrone 10 mg/m2 day 1, followed by 5‐fluorouracil 375 mg/m2 day 1‐5, and high‐dose leucovorin 500 mg/m2 day 1‐5 given every 28 days. There was one complete and four partial responses for an objective response rate of 30% and 41% stable disease. The major toxicities were hematologic and gastrointestinal. This regimen has activity in metastatic breast cancer comparable to conventional and/or standard chemotherapy regimens for advanced disease. © 1994 Wiley‐Liss, Inc.
Radiation therapy for alveolar soft‐part sarcoma
Authors: Sherman N. , Vavilala M. , Pollock R. , Romsdahl M. , Jaffe N. 
Published: February 2007

AbstractA clinical experience with radiotherapy in 18 patients with alveolar soft‐part sarcoma is presented. Adjuvant radiotherapy was associated with prolonged local control in six of six patients without metastatic disease at diagnosis; later one patient relapsed systematically. Meaningful palliation was achieved in all patients with extra‐skeletal (and possibly skeletal) metastatic disease. Radiation therapy may be beneficial for patients with alveolar soft‐part sarcoma by enhancing local control achieved with limited surgery, by retarding progression of metastatic deposits, and by providing meaningful palliation. © 1994 wiiey‐Liss, inc.
Peripheral T‐cell lymphoma in childhood: A report of five cases in Taiwan
Authors: Lin Kai‐Hsin , Su Ih‐Jen , Chen Rong‐Long , Lin Dong‐Tsamn , Tien Hwei‐Fang , Chen Bo‐Wen , Lin Kuo‐Sin 
Published: February 2007

AbstractWe encountered five children with peripheral T‐cell lymphoma (PTL) at National Taiwan University Hospital (NTUH) from 1985–1989. The patients were four boys and one girl, aged between 5 and 13 years. The duration of prediagnostic symptoms varied from 1 month to 5 years. All had pyrexia and lymphadenopathy; one had a prolonged history of granulomatosis with repeated infection. Four had hepatosplenomegaly. One patient presented with diffuse pulmonary infiltration and impending respiratory failure. All patients were negative for human T‐cell leukemia virus (HTLV)‐I antibody, and positive for HBsAg. Four patients who had EBV‐viral capsid antigen (VCA) IgG and who were IgM tested were positive for EBV‐VCA IgG, but only two had evidence of active EBV infection. Tumor cell markers were examined and showed the following phenotypes: all patients were CD2, CD3, and CD7 positive but CD19 and CD20 negative; three patients were CD4 positive and CD8 negative; the other two patients were CD4 negative and CD8 positive. Four patients died 2–7 months after diagnosis. The remaining patient received allogeneic bone marrow transplantation and has survived free of disease for more than 22 months after transplant. Our five cases reconfirm the high frequency of diagnostic delay, the heterogenous immunophenotypes, high mortality, and poor responsiveness to conventional therapy for PTL. Bone marrow transplantation in the early stage might be a possible cure of this disease. ©1994 Wiley‐Liss, inc.
Juvenile xanthogranuloma and acute leukemia: A case report
Authors: Rotte Joan J. , de Vaan Gérard A. M. , Koopman Roland J. J. 
Published: February 2007

AbstractJuvenile xanthogranuloma (JXG) is a rare benign disease of the skin. It is seen in combination with juvenile chronic myelo‐monocytic leukemia (JCML) and/or neurofibromatosis type 1 (NF1). The association with acute lymphoblastic leukemia is hardly mentioned in the literature. A case report of this rare combination is described and a review of the literature is given. © 1994Wiley‐Liss, Inc.
Epidural metastasis in Wilms' tumor: A case report and review of the literature
Authors: Darendeliler Emin , Ayan Inci , Kebudi Rejin , Aǧaoǧlu Leyla , Bilge Nijad , Kinay Münir 
Published: February 2007

AbstractSpinal canal involvement is not a common pattern of metastasis in Wilms' tumor. Although early detection and treatment can achieve improvement of neurological deficit, mortality remains high. We present a 5‐year‐old girl who had an epidural metastasis while she was receiving chemotherapy for stage IV Wilms' tumor. Within 2 months following laminectomy, total removal of tumor, radiotherapy, and adjuvant chemotherapy some of the neurological signs improved. © 1994 Wiley‐Liss, Inc.
Treatment strategy for disseminated langerhans cell histiocytosis
Authors: Gadner Helmut , Heitger Andreas , Grois Nicole , Gatterer‐Menz Irmgard , Ladisch Stephan 
Published: February 2007

AbstractTreatment of Langerhans cell histiocytosis (LCH) remains problematic. To test the hypothesis that rapid initiation and longterm continuation of chemotherapy can improve survival and reduce recurrence and late consequences of disseminated LCH, we have completed a prospective clinical trial (DAL HX‐83). One hundred six newly diagnosed patients were stratified into three risk groups (A: multifocal bone disease [n = 28]; B: soft tissue involvement without organ dysfunction [n = 57]; C: organ dysfunction [n = 21]). All patients received an identical initial 6‐week treatment (etoposide [VP‐16], prednisone, and vinblastine), and continuation treatment for 1 year, slightly adapted according to stratification at diagnosis. It included oral 6‐mercaptopurine and eight pulses of vinblastine and prednisone for all patients, plus VP‐16 in group B and VP‐16 and methotrexate in group C. Eighty‐nine percent and 91% of patients in groups A and B and 67% of the most severely affected group C, achieved complete resolution of disease. The speed of resolution was rapid (median 4 months) and independent of disease severity. The frequency of recurrence after initial resolution was low (12%, 23%, and 42% in groups A, B, and C); overall fully 77% of patients have remained free of recurrence. Permanent consequences developed after diagnosis in 20% of the patients. Diabetes insipidus after initiation of treatment occurred in only 10% of patients. Mortality (9%) was limited to patients of groups B (two patients) and C (eight patients). Finally, among the 106 patients treated by DAL HX‐83 none have developed a malignancy (median follow‐up 6 years, 9 months). The shorter duration of active disease, low rate of recurrence and permanent consequences, and improved survival among patients with poor prognosis support the strategy of rapid initiation of a predefined prolonged treatment upon the diagnosis of disseminated LCH. © 1994 Wiley‐Liss, Inc.
Hypertrophic pulmonary osteoarthropathy in a child with thymic carcinoma: An Unusual presentation in childhood
Authors: Ilhan Inci , Kutluk Tezer , Göǧüş Safiye , Besim Aytekin , Büyükpamukçu Münevver 
Published: February 2007

AbstractWe report here a case of intrathoracic undifferentiated carcinoma in the thymus with hypertrophic pulmonary osteoarthropathy in a 13‐year‐old girl. The association of the two conditions is very rare. © 1994 Wiley‐Liss, Inc.